Robert Jr. Baltera Purchases 25,000 Shares of Palisade Bio (NASDAQ:PALI) Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera acquired 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The stock was bought at an average price of $1.96 per share, with a total value of $49,000.00. Following the completion of the acquisition, the director directly owned 461,904 shares of the company’s stock, valued at $905,331.84. This trade represents a 5.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Robert Jr. Baltera also recently made the following trade(s):

• On Wednesday, July 8th, Robert Jr. Baltera bought 20,000 shares of Palisade Bio stock. The shares were bought at an average cost of $1.99 per share, for a total transaction of $39,800.00.
• On Tuesday, July 7th, Robert Jr. Baltera purchased 30,000 shares of Palisade Bio stock. The stock was bought at an average price of $2.03 per share, for a total transaction of $60,900.00.
• On Monday, July 6th, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The stock was bought at an average cost of $2.05 per share, with a total value of $41,000.00.
• On Thursday, July 2nd, Robert Jr. Baltera acquired 10,000 shares of Palisade Bio stock. The shares were bought at an average price of $1.98 per share, with a total value of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera acquired 20,000 shares of Palisade Bio stock. The stock was bought at an average cost of $1.98 per share, for a total transaction of $39,600.00.

Palisade Bio Trading Down 0.5%

PALI stock traded down $0.01 during trading on Friday, hitting $1.96. The company had a trading volume of 3,452,719 shares, compared to its average volume of 4,494,371. The stock has a market cap of $340.22 million, a PE ratio of -1.94 and a beta of 1.50. The business has a 50-day moving average of $1.92 and a 200-day moving average of $1.92. Palisade Bio, Inc. has a one year low of $0.53 and a one year high of $2.85.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Research analysts forecast that Palisade Bio, Inc. will post -0.25 EPS for the current year.

Institutional Trading of Palisade Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC acquired a new position in Palisade Bio during the 4th quarter worth approximately $28,318,000. Commodore Capital LP bought a new stake in shares of Palisade Bio during the fourth quarter valued at approximately $26,896,000. Janus Henderson Group PLC bought a new stake in shares of Palisade Bio during the fourth quarter valued at approximately $24,822,000. RA Capital Management L.P. acquired a new position in shares of Palisade Bio during the fourth quarter worth approximately $16,742,000. Finally, Eversept Partners LP bought a new position in shares of Palisade Bio in the 4th quarter worth $12,670,000. 11.79% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on PALI shares. Oppenheimer set a $7.00 price target on shares of Palisade Bio in a research report on Tuesday, June 30th. LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Weiss Ratings upgraded Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 29th. Wolfe Research initiated coverage on Palisade Bio in a report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $2.00 price target on shares of Palisade Bio in a research note on Tuesday, June 30th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $8.83.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.